Skip to main content
Top

09-06-2024 | Osteoarthrosis | REVIEW ARTICLE

Evidence for the use of cannabis-based medicines in osteoarthritis: a scoping review

Authors: Andrew T. Y. Xiao, Tarek Turk, Karanvir Deol, Susan Zhang, Heba A. T. Aref, Alexandra Campbell, Allyson Jones, Shelby S. Yamamoto, Liz Dennett, Linda Kolewaski, Cheryl A. Sadowski, Elaine A. Yacyshyn

Published in: Clinical Rheumatology

Login to get access

Abstract

The purpose of this study was to conduct a scoping review to describe the evidence on the efficacy and safety of using cannabis-based medicines for osteoarthritis. The review was conducted following the framework proposed by Arksey and O’Malley and reported following PRISMA extension for scoping reviews guidelines. We conducted a comprehensive search across various databases including MEDLINE, Embase, Cochrane Library, CINAHL, Scopus, and Proquest, spanning from inception of each database to March 2023. We retrieved 2533 citations, and after deduplication, title and abstract screening, and full-text screening, 10 articles were included for analysis. These studies were composed of randomized-controlled trials (n = 4/10), cross-sectional surveys (n = 3/10), case studies (n = 2/10), and a cohort study (n = 1/10). Evidence for using cannabis-based medicines was mixed, with just 60% (n = 6/10) of included studies reporting statistically significant improvements in pain. Studies with larger samples sizes and longer durations of exposure did not find significant benefits for pain. The few adverse effects reported were generally mild and affected a minority of participants. Several studies also discovered that cannabis-based medicines were associated with a reduction in opioid use. Currently available data on the use of cannabis-based medicines in osteoarthritis is insufficient to make recommendations. Future research should address concerns regarding small sample sizes and short treatment durations to provide a more robust evidence base.
Key Points
Current evidence remains mixed; studies that found a positive benefit with using cannabis-based medicines had limitations with small sample sizes and short durations of exposure
The use of cannabis-based medicines in osteoarthritis appears to be generally well tolerated, adverse effects are mild and experienced by a minority of participants
Cannabis-based medicines may decrease the use of opioids in patients with osteoarthritis
Future research should address the gaps in long-term efficacy and safety data
Appendix
Available only for authorised users
Literature
18.
go back to reference Peters MDJ, Godfrey CM, McInerney P, Soares CB, Khalil H, Parker D (2015) The Joanna Briggs Institute reviewers' manual 2015: methodology for JBI scoping reviews Peters MDJ, Godfrey CM, McInerney P, Soares CB, Khalil H, Parker D (2015) The Joanna Briggs Institute reviewers' manual 2015: methodology for JBI scoping reviews
26.
32.
go back to reference Wang A, Lo A, Ubhi K, Cameron T (2021) Small and transient effect of cannabis oil for osteoarthritis-related joint pain: a case report. Can J Hosp Pharm 74(2):156–158PubMedPubMedCentral Wang A, Lo A, Ubhi K, Cameron T (2021) Small and transient effect of cannabis oil for osteoarthritis-related joint pain: a case report. Can J Hosp Pharm 74(2):156–158PubMedPubMedCentral
43.
go back to reference Deveza LA, Nelson AE, Loeser RF (2019) Phenotypes of osteoarthritis: current state and future implications. Clin Exp Rheumatol 37 Suppl 120(5):64–72PubMed Deveza LA, Nelson AE, Loeser RF (2019) Phenotypes of osteoarthritis: current state and future implications. Clin Exp Rheumatol 37 Suppl 120(5):64–72PubMed
Metadata
Title
Evidence for the use of cannabis-based medicines in osteoarthritis: a scoping review
Authors
Andrew T. Y. Xiao
Tarek Turk
Karanvir Deol
Susan Zhang
Heba A. T. Aref
Alexandra Campbell
Allyson Jones
Shelby S. Yamamoto
Liz Dennett
Linda Kolewaski
Cheryl A. Sadowski
Elaine A. Yacyshyn
Publication date
09-06-2024
Publisher
Springer International Publishing
Published in
Clinical Rheumatology
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-024-07001-7
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare